Literature DB >> 78927

Decreased levels of collagen mRNA in rous sarcoma virus-transformed chick embryo fibroblasts.

B H Howard, S L Adams, M E Sobel, I Pastan, B de Crombrugghe.   

Abstract

We have found that double-stranded cDNA synthesized in extended reactions by avian myeloblastosis virus reverse transcriptase is suitable substrate for a variety of restriction endonucleases. Experiments in which rabbit reticulocyte mRNA was reverse-transcribed and restricted to generate beta-globin-specifihe nucleotide sequence of beta-globin mRNA. This method has been applied to study collagen mRNA synthesis in normal and Rous sarcoma virus (RSV)-transformed chick embryo fibroblasts. Characteristic sets of collagen cDNA restriction fragments were produced from RNA fractions rich in collagen message activity. These sets of cDNA fragments, generated by the restriction endonucleases Hae III and Hap II, provided a convenient marker for the presence of collagen mRNA sequences. Equal quantities of high molecular weight mRNA from chick embryo fibroblasts (CEF) and RSV-CEF were reverse-transcribed and the resulting cDNA was restricted. The relative yields of collagen cDNA fragments from such reactions strongly suggest that the decrease in functional collagen RNA following RSV-induced transformation of CEF represents a decrease in the copy number of collagen messenger sequences. The potential of this approach for the study of regulation in other systems is discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 78927

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Translation of embryonic-chick tendon procollagen messenger ribonucleic acid in two cell-free protein-synthesizing systems.

Authors:  K S Cheah; M E Grant; D S Jackson
Journal:  Biochem J       Date:  1979-07-15       Impact factor: 3.857

Review 2.  Control of myogenic differentiation by cellular oncogenes.

Authors:  M D Schneider; E N Olson
Journal:  Mol Neurobiol       Date:  1988       Impact factor: 5.590

3.  Control of types I and II collagen and fibronectin gene expression in chondrocytes delineated by viral transformation.

Authors:  E S Allebach; D Boettiger; M Pacifici; S L Adams
Journal:  Mol Cell Biol       Date:  1985-05       Impact factor: 4.272

4.  Neoplastic transformation inactivates specific trans-acting factor(s) required for the expression of the thyroglobulin gene.

Authors:  V E Avvedimento; A Musti; A Fusco; M J Bonapace; R Di Lauro
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

5.  Deletion analysis of the mouse alpha 1(III) collagen promoter.

Authors:  M Mudryj; B de Crombrugghe
Journal:  Nucleic Acids Res       Date:  1988-08-11       Impact factor: 16.971

6.  Translation and characterization of messenger RNAs in differentiating chicken cartilage.

Authors:  W B Upholt; B M Vertel; A Dorfman
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

7.  Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis fibroblasts.

Authors:  S A Jimenez; G Feldman; R I Bashey; R Bienkowski; J Rosenbloom
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

8.  Transcriptional control of the mouse alpha 2(I) collagen gene: functional deletion analysis of the promoter and evidence for cell-specific expression.

Authors:  A Schmidt; P Rossi; B de Crombrugghe
Journal:  Mol Cell Biol       Date:  1986-02       Impact factor: 4.272

9.  Stimulation of alpha 1 (I) procollagen gene expression in NIH-3T3 cells by the human T cell leukemia virus type 1 (HTLV-1) Tax gene.

Authors:  E Muñoz; D Suri; S Amini; K Khalili; S A Jiménez
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

10.  Loss of type I procollagen gene expression in SV40-transformed human fibroblasts is accompanied by hypermethylation of these genes.

Authors:  M I Parker; K Judge; W Gevers
Journal:  Nucleic Acids Res       Date:  1982-10-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.